I have seen it worn on the buttons and displayed on bumper stickers, but in the course of this inaugural 'bone' issue, I hope you find that we as urologists do more than just 'fix the plumbing'. Through combinations of genetics, diet, medical therapies, or surgical interventions, urology patients are susceptible to bone loss and skeletal events. The articles presented in this section embody one of the first-ever complete reviews on urologic-related bone topics and reveal what we as urologists can do to 'reinforce the walls'. These outstanding studies, highlighting both the strengths and the weaknesses of our literature, are loosely divided into prostate cancer and androgen effects, urinary diversion effects, and renal effects (stone disease, donor and partial nephrectomy) on bone health.
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PROSTATE AND ANDROGEN
Drs Gartrell and Saad (pp. 595-600) open by reviewing the incidence of skeletal-related events (SREs) in men with metastatic prostate cancer and close by evaluating the latest advances in SRE prevention, including agents that target osteoclasts (zolendronic acid and denosumab), androgens (abiraterone and enzalutamide), bone osteoblastic activity (radium-223), and tyrosine kinase (cabozantinib). Drs Skolarus, Caram, and Shahinian (pp. 601-607) focus on the pharmaceutical agents (antiresorptives, calcium, and vitamin D) and other strategies (exercise and intermittent use) that target bone loss associated with androgen deprivation therapy (ADT) in the nonmetastatic prostate cancer setting. They convincingly argue that, despite the preservation of bone mineral density by a variety of strategies, none of these approaches has convincingly reduced the fracture outcomes in this patient population and emphasize the importance of using ADT only when clinically beneficial. Last, Dr Michael Irwig (pp. 608-613) appraises the most recent literature in the setting of male hypogonadism and the bone-testis axis, including new studies of the boneformative marker osteocalcin and vitamin D. Similar to the previous authors, he concludes that, despite a number of small studies showing that testosterone replacement therapy can increase bone mineral density in hypogonadal men, the benefit of testosterone replacement in bone fracture prevention is uncertain and will require high-quality, long-term investigational trials in the future.
URINARY DIVERSION
The often neglected, complex topic of bone loss following urinary diversion is addressed by two groups. First, Drs Vyas and Crispen (pp. 614-618) review the pathophysiology behind the development of acidosis following urinary diversion. They then summarize the results from a number of adult case series, reporting the incidence of both chronic metabolic acidosis and bone disease to range from 2 to 15%. This seemingly 'low' incidence, however, appears much higher when one considers that the prevalence of osteoporosis in the USA is approximately 2.5% (10 million). Although fracture risk has not been studied well in the pediatric population, Drs Hensle, Mingin, and Fam (pp. 619-623) provide evidence that childhood enterocystoplasty can lead to chronic metabolic acidosis and bone mineral density loss that can require lifelong bicarbonate replacement. Interestingly, the authors review several studies that suggest augmentation status is not as important for long-term bone health as the child's neurological and activity status. For urologists who regularly follow these patients, high clinical suspicion and a detailed activity history may help identify children who are at high risk for bone loss.
